Donald W. Mann
Pfizer
12 Papers
168 Citations
Donald W. Mann is an academic researcher from Pfizer. The author has contributed to research in topics: Pyrazole & Cancer. The author has an hindex of 8, co-authored 12 publications.
Chat about Author
Papers
5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog.
Subas M. Sakya,Kristin M. Lundy DeMello,Martha L. Minich,Bryson Rast,Andrei Shavnya,Robert J. Rafka,David A. Koss,Cheng Hengmiao,Jin Li,Burton H. Jaynes,Ziegler Carl B,Donald W. Mann,Carol F. Petras,Scott B. Seibel,Annette M. Silvia,David M. George,Lisa A. Lund,Suzanne H. St. Denis,Anne Hickman,Michelle L. Haven,Michael P. Lynch +20 more
TL;DR: Structure-activity relationship studies of the novel 2-di and trifluoromethyl-5-alkylamino pyrazo-1-yl derivatives led to the identification of 2e as lead with potent in vitro activity, selectivity, and in vivo activity in dogs and cats.
54
Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors.
Cheng Hengmiao,Kristin M. Lundy DeMello,Jin Li,Subas M. Sakya,Kazuo Ando,K. Kawamura,Tomoki Kato,Robert J. Rafka,Burton H. Jaynes,Ziegler Carl B,Rod Stevens,Lisa A. Lund,Donald W. Mann,Carolyn Rose Kilroy,Michelle L. Haven,Erik L. Nimz,Jason K. Dutra,Chao Li,Martha L. Minich,Nicole L. Kolosko,Carol F. Petras,Annette M. Silvia,Scott B. Seibel +22 more
TL;DR: The discovery of heteroaryl-phenyl-substituted pyrazole derivatives as canine selective COX-2 inhibitors as well as structure-activity relationship (SAR) studies of this class of compounds led to the identification of compound 1.
43
Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.
Jin Li,Kristin M. Lundy DeMello,Henry Cheng,Subas M. Sakya,Bronk Brian Scott,Robert J. Rafka,Burton H. Jaynes,Ziegler Carl B,Carolyn Rose Kilroy,Donald W. Mann,Eric L. Nimz,Michael P. Lynch,Michelle L. Haven,Nicole L. Kolosko,Martha L. Minich,Chao Li,Jason K. Dutra,Bryson Rast,Rhonda M. Crosson,Morton Barry James,Glen W. Kirk,Kathleen M. Callaghan,David A. Koss,Andrei Shavnya,Lisa A. Lund,Scott B. Seibel,Carol F. Petras,Annette M. Silvia +27 more
TL;DR: The in vitro and in vivo activity of 12a for the canine COX-2 enzyme as well as its in vivo efficacy and pharmacokinetic properties in dog are highlighted.
38
5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure–activity relationship studies of 5-alkylethers and 5-thioethers
Subas M. Sakya,Cheng Hengmiao,Kristin M. Lundy DeMello,Andrei Shavnya,Martha L. Minich,Bryson Rast,Jason K. Dutra,Chao Li,Robert J. Rafka,David A. Koss,Jin Li,Burton H. Jaynes,Ziegler Carl B,Donald W. Mann,Carol F. Petras,Scott B. Seibel,Annette M. Silvia,David M. George,Anne Hickman,Michelle L. Haven,Michael P. Lynch +20 more
TL;DR: Structure-activity relationship (SAR) studies of novel 2-[3-trifluoromethyl-5-alkyl(thio)ether pyrazo-1-yl]-5-methanesulfonyl pyridine derivatives for canine COX enzymes are described, with excellent potency and selectivity and less selective than the ether analogs in a canine whole blood COX-2 assay.
35
Comparative structure–activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition
Subas M. Sakya,Andrei Shavnya,Cheng Hengmiao,Chao Li,Bryson Rast,Jin Li,David A. Koss,Burton H. Jaynes,Donald W. Mann,Carol F. Petras,Scott B. Seibel,Michelle L. Haven,Michael P. Lynch +12 more
TL;DR: Both series of novel 5-alkyl and 5-aryl/heteroaryl substituted 1,2,4-triazoles are described, suggesting the increased binding contribution of the hydrophobic side chains.
13